ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1464
CHEMBL1464
Compound Name WARFARIN
ChEMBL Synonyms ATHROMBIN | WARFARIN POTASSIUM | COUMADIN | PANWARFIN | WARFARIN | ATHROMBIN-K | MAREVAN | JANTOVEN | WARFARIN SODIUM
Max Phase 4 (Approved)
Trade Names JANTOVEN | MAREVAN | ATHROMBIN | WARFARIN SODIUM | PANWARFIN | ATHROMBIN-K | COUMADIN
Molecular Formula C19H16O4

Additional synonyms for CHEMBL1464 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CC(=O)CC(C1=C(O)c2ccccc2OC1=O)c3ccccc3
Standard InChI InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14 ...
Download InChI
Standard InChI Key PJVWKTKQMONHTI-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Curated Drug Metabolism Pathways
  • DrugMatrix
  • Orange Book
  • Patent Bioactivity Data
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1464

Molecule Features

CHEMBL1464 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Racemic Mixture Prodrug:N Oral:Y Parenteral:Y Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor Vitamin k epoxide reductase complex subunit 1 isoform 1 DailyMed PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Atrial FibrillationD001281EFO:0000275atrial fibrillation3ClinicalTrials
ClinicalTrials
ClinicalTrials
Diabetes MellitusD003920EFO:0000400diabetes mellitus1ClinicalTrials
OsteoarthritisD010003EFO:0002506osteoarthritis1ClinicalTrials
Pulmonary EmbolismD011655EFO:0003827pulmonary embolism3ClinicalTrials
ThrombocytopeniaD0139213ClinicalTrials
HypoprothrombinemiasD007020Orphanet:325Congenital factor II deficiency1ClinicalTrials
Multiple Sclerosis, Relapsing-RemittingD020529EFO:0003929relapsing-remitting multiple sclerosis3ClinicalTrials
PsoriasisD011565EFO:0000676psoriasis1ClinicalTrials
Idiopathic Pulmonary FibrosisD054990EFO:0000768idiopathic pulmonary fibrosis3ClinicalTrials
Myocardial IschemiaD017202EFO:1001375Myocardial Ischemia3ClinicalTrials
NauseaD009325EFO:0006911Chemotherapy-induced nausea and vomiting1ClinicalTrials
ThrombosisD013927HP:0004419Recurrent thrombophlebitis4ATC
Urinary Bladder, OveractiveD053201EFO:1000781overactive bladder1ClinicalTrials
Venous ThrombosisD020246EFO:0003907deep vein thrombosis3ClinicalTrials
ClinicalTrials
Alzheimer DiseaseD000544EFO:0000249Alzheimers disease1ClinicalTrials
Crohn DiseaseD003424EFO:0000384Crohn's disease1ClinicalTrials
DiseaseD004194EFO:0000408disease2ClinicalTrials
Heart FailureD006333EFO:0003144heart failure3ClinicalTrials
Myocardial InfarctionD009203EFO:0000612myocardial infarction2ClinicalTrials
NeoplasmsD009369EFO:0000311cancer1ClinicalTrials
Venous ThromboembolismD054556EFO:0004286venous thromboembolism3ClinicalTrials
ClinicalTrials
Atrial FlutterD001282EFO:0003911atrial flutter3ClinicalTrials
Dermatitis, AtopicD003876EFO:0000274atopic eczema1ClinicalTrials
EpilepsyD004827EFO:0000474epilepsy1ClinicalTrials
Essential HypertensionD000075222EFO:1002032primary hypertension1ClinicalTrials
LymphomaD008223EFO:0000574lymphoma1ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm1ClinicalTrials
PregnancyD011247EFO:0002950pregnancy3ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma3ClinicalTrials
Coronary Artery DiseaseD003324EFO:0000378coronary artery disease3ClinicalTrials
Depressive DisorderD003866EFO:0003761unipolar depression1ClinicalTrials
Hypertension, PulmonaryD006976EFO:0001361pulmonary hypertension2ClinicalTrials
Rheumatic Heart DiseaseD012214EFO:1001161rheumatic heart disease3ClinicalTrials
ThrombophlebitisD013924HP:0004418Thrombophlebitis1ClinicalTrials
Venous ThrombosisD020246HP:0004936Venous thrombosis3ClinicalTrials
ClinicalTrials
Arthritis, RheumatoidD001172EFO:0000685rheumatoid arthritis1ClinicalTrials
Parkinson DiseaseD010300EFO:0002508Parkinson's disease1ClinicalTrials
Peripheral Vascular DiseasesD016491EFO:0003875peripheral vascular disease3ClinicalTrials
StrokeD020521EFO:0000712stroke3ClinicalTrials
Cardiovascular DiseasesD002318EFO:0000319cardiovascular disease1ClinicalTrials
Diabetes Mellitus, Type 2D003924EFO:0001360type II diabetes mellitus1ClinicalTrials
Heart DiseasesD006331EFO:0003777heart disease2ClinicalTrials
Hematologic NeoplasmsD019337EFO:0001642lymphoid neoplasm1ClinicalTrials
HypertriglyceridemiaD015228EFO:0004211Hypertriglyceridemia1ClinicalTrials
Liver CirrhosisD008103EFO:0001422cirrhosis of liver2ClinicalTrials

Clinical Data

ClinicalTrials.gov WARFARIN
The Cochrane Collaboration WARFARIN

Metabolites for CHEMBL1464

Open in full screen

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1464. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL3623 Quinone reductase 1) Homo sapiens 1.000
CHEMBL243 Human immunodeficiency virus type 1 protease Human immunodeficiency virus 1 0.994
CHEMBL312 Arachidonate 5-lipoxygenase Rattus norvegicus 0.952
CHEMBL2857 Human rhinovirus A protease Human rhinovirus sp. 0.807
CHEMBL3687 Arachidonate 12-lipoxygenase Homo sapiens 0.714
CHEMBL5763 Cholinesterase Equus caballus 0.638
CHEMBL1293226 Lysine-specific demethylase 4D-like Homo sapiens 0.504
CHEMBL4159 Endoplasmic reticulum-associated amyloid beta-peptide-binding protein Homo sapiens 0.231
CHEMBL1963 Thyroid stimulating hormone receptor Homo sapiens 0.209



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL3623 Quinone reductase 1) Homo sapiens 1.000
CHEMBL243 Human immunodeficiency virus type 1 protease Human immunodeficiency virus 1 0.995
CHEMBL312 Arachidonate 5-lipoxygenase Rattus norvegicus 0.838
CHEMBL1293226 Lysine-specific demethylase 4D-like Homo sapiens 0.666
CHEMBL3251 Nuclear factor NF-kappa-B p105 subunit Homo sapiens 0.584
CHEMBL215 Arachidonate 5-lipoxygenase Homo sapiens 0.499
CHEMBL2857 Human rhinovirus A protease Human rhinovirus sp. 0.258

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
308.3 308.1049 3.61 4 67.51 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
4 1 0 4 1 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
4.5 - 3.13 .33 3 23 0.75

Structural Alerts

There are 5 structural alerts for CHEMBL1464. To view alerts please click here.

Compound Cross References

ATC B - BLOOD AND BLOOD FORMING ORGANS
B01 - ANTITHROMBOTIC AGENTS
B01A - ANTITHROMBOTIC AGENTS
B01AA - Vitamin K antagonists
B01AA03 - warfarin

ChemSpider ChemSpider:PJVWKTKQMONHTI-UHFFFAOYSA-N
DailyMed warfarin sodium
PubChem SID: 144206736 SID: 144209380 SID: 144210849 SID: 174006926 SID: 26748308 SID: 26754489
Wikipedia Warfarin

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1464



ACToR 81-81-2
BindingDB 50343352
Brenda 75367 78827 75368 132281 719
ChEBI 87732
DrugBank DB00682
DrugCentral 2847
eMolecules 510315
EPA CompTox Dashboard DTXSID5023742
Guide to Pharmacology 6853
Human Metabolome Database HMDB0001935
IBM Patent System 2D11F259B29BBC77573CA48D07381AC7
KEGG Ligand C01541
LINCS LSM-1405
Mcule MCULE-1618253893
MolPort MolPort-001-787-822
Nikkaji J3.862H
PubChem 54678486
PubChem: Thomson Pharma 14825580
SureChEMBL SCHEMBL3689

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/PJVWKTKQMONHTI-UHFFFAOYSA-N spacer
spacer